ImmuCellvsJohnson & Johnson

ICCC and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

ICCC

ImmuCell Corporation

$11.33

Value $103M

-0.79%
ICCC's page

ImmuCell (ICCC) has a market value of $103M and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, ICCC moved +109.8% and JNJ +45.4%. The P/E is 54.5 for ICCC and 41.7 for JNJ. Dividend yield: ICCC none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ICCC$103M

    JNJ$672B

    JNJ is 6,553 times ICCC

  • Revenue, 12 months

    ICCC$33M

    JNJ$99.3B

    JNJ is 2,991 times ICCC

  • Net income, 12 months

    ICCC$1.9M

    JNJ$16.1B

    JNJ is 8,563 times ICCC

  • Operating margin

    ICCC14.5%

    JNJ–

  • ROIC

    ICCC9.8%

    JNJ12.4%

    2.6 points apart

  • P/E

    ICCC54.5

    JNJ41.7

    ICCC is 1.3 times JNJ

  • Dividend yield

    ICCC0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    ICCC+24.5%

    JNJ+97.0%

    72.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ICCC+24.5%

JNJ+97.0%

5010015020020222023202420252026
Returns by period
PeriodICCCWith dividendsJNJWith dividends
1 year since November 14, 2025+109.8%Price +109.8%+45.4%Price +42.2%
3 years since November 17, 2023+138.0%+33.5% a yearPrice +138.0%+102.6%+26.5% a yearPrice +86.1%
5 years since November 16, 2021+24.5%+4.5% a yearPrice +24.5%+97.0%+14.5% a yearPrice +71.3%
10 years since November 17, 2016+123.9%+8.4% a yearPrice +123.9%+213.7%+12.1% a yearPrice +139.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ICCCImmuCellJNJJohnson & Johnson

Valuation

ICCCJNJ
Valuation
Price$11.33$278.70
Market value$103M$672B
Enterprise value (EV)$102M$699B
P/E54.541.7
P/E, 5-year median–21.9
P/B3.18.2
EV/EBIT21.339.4
Free cash flow yield5.3%3.1%

Results and growth

ICCCJNJ
Results and growth
Revenue, 12 months$33M$99.3B
Net income, 12 months$1.9M$16.1B
Free cash flow, 12 months$5.4M$20.6B
Earnings per share, 12 months$0.19$6.59
Revenue growth, year on year4.3%6.1%
Revenue growth a year, past+12.5%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

ICCCJNJ
Margins and returns on capital
Gross margin40.8%67.6%
Operating margin14.5%–
Net margin5.7%16.2%
ROIC9.8%12.4%
ROE6.3%19.7%

Balance sheet

ICCCJNJ
Balance sheet
Cash$7.9M$17.2B
Total debt$12M$44.7B
Net debt / EBITDA0.01.1
Interest cover12.2×18.0×

Dividends and buybacks

ICCCJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ICCC or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, ImmuCell or Johnson & Johnson?

By market value, Johnson & Johnson ($672B) is about 6,552.6 times ImmuCell ($103M), at today's prices.

How did ICCC and JNJ stock do over the last 10 years?

Since November 17, 2016, ICCC's price moved +123.9% and JNJ's +139.1%. With dividends: ICCC +123.9% (+8.4% a year), JNJ +213.7% (+12.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ICCC or JNJ?

The dividend yield at today's price is none for ImmuCell and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of ICCC and JNJ?

At today's price, the P/E is 54.5 for ICCC and 41.7 for JNJ. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, ImmuCell or Johnson & Johnson?

Over the last twelve months, the net margin was 5.7% for ImmuCell and 16.2% for Johnson & Johnson, and the operating margin 14.5% and –. Revenue was $33M and $99.3B.

Which is the better investment, ImmuCell or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.